Cargando…

Clinical Use of DPP-4 Inhibitors

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk. Their efficacy potential to lower HbA1c is in the range between 0.5 and...

Descripción completa

Detalles Bibliográficos
Autor principal: Gallwitz, Baptist
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593043/
https://www.ncbi.nlm.nih.gov/pubmed/31275246
http://dx.doi.org/10.3389/fendo.2019.00389